Cardiovascular Research Foundation

🚀 Ignite Innovation, Education, and Connection at #TCT2024! 🌟 Ready to unleash your potential? Join us in Washington, D.C., to explore groundbreaking science and take your practice to the next level! 🌐✨ Don't miss out—secure your spot today before rates increase on September 11! ➡️ https://ow.ly/7K7j50SXe6e #cardiology #interventionalcardiology Daniel Burkhoff David Cohen George Dangas, MD, MACC, MSCAI Juan Granada Akiko Maehara Roxana Mehran Gary Mintz Sahil Parikh Tricia Rawh

In a blink of an eye Day 2 of #TCT2024 has come to a close! So proud to be apart of this team! #NewYork-Presbyterian Hospital #Columbia University Irving Medical Center #Weill Cornell Medicine #Cardiovascular Research Foundation

Yesterday, our team at the Heart Center Aalst had the absolute honour of performing two live cases streamed directly to the Cardiovascular Research Foundation #TCT2024 conference in Washington – one of the world’s most prestigious stages in interventional cardiology! 🎥🌐 It was a unique opportunity to showcase two key aspects of our work: first, how we integrate CT into our daily PCI practice, and second, how our procedural flow is designed for coronary function testing specifically in #ANOCA patients. Together with Jeroen Sonck, we demonstrated a #CTguidedPCI using information from CCTA, nowadays almost always part of the workup in angina patients and thus freely available. With Bernard De Bruyne, we showcased our robust and standardised approach to coronary function testing for #ANOCA patients. These moments remind me how incredibly lucky and privileged I am to be able to do this work and be surrounded by inspiring colleagues. To everyone involved, thank you for your commitment, energy, and flexibility. 💪💙 Carlos Collet Bortone, MD, PhD Jeroen Sonck Bernard De Bruyne Eric Wyffels Marc Vanderheyden Jozef Bartunek Heart Center Aalst Els Van Laer

✨ The final day of #TCT2024 is almost here! 🌟 Get ready for a full day packed with world-class education and hands-on training. 📅 Plan ahead and make the most of it: https://ow.ly/Zq4Z50TT0kG #InterventionalCardiology

Fresh insights from the PROTECTED TAVR Trial! 🧠🫀 US cohort results on cerebral embolic protection in TAVR were just unveiled at #TCT2024 and published in JAMA Cardiology. https://lnkd.in/e-3ss9Vi #interventionalcardiology 

📍Washington 🇺🇸 #TCT2024 🫀Cardiovascular Research Foundation

Meeting again with great mentors and friends at TCT 2024 in Washington DC 🌎🇺🇸 TCTMD Cardiovascular Research Foundation Our VR-based Multidisciplinary Heart Team study was presented at the AI in Structural Heart Diseases session (Aimedis) and our FFR-CT study was presented with simultaneous publication at EuroIntervention 🫀 https://lnkd.in/e3tYU729

Honored and humbled to share that I’ve been awarded the Linnemeier Young Investigator Award at #TCT2024! Cardiovascular Research Foundation A huge congratulations to my fellow finalists, Kashish Goel , Tim P Van de Hoef, and my incredible co-winner Alexander Fanaroff It’s an absolute privilege to stand alongside such talented and inspiring minds in the field. Each of you is driving forward our understanding of cardiovascular health, and I’m excited to see the impact we’ll continue to make together. Thank you to everyone who has supported this journey— my colleagues at University of California, San Francisco , University of Ottawa Heart Institute and Institut Cardiologie de Montréal who supported me and continue to support my journey of accelerating the adoption of #AI in healthcare . Thanks also to my family, my fiancée Lilliane and friends who enable my almost full dedication to this field !! #TCT #Cardiology #Research

Congratulations to PennMedicine superstar physician scientist Dr. Alex Fanaroff on being awarded the Thomas Linnemeier Young Investigator Award today at Cardiovascular Research Foundation TCT 2024! Alex has published over 100 manuscripts, runs several important clinical trials at the intersection of behavioral economics and cardiovascular medicine, and has already obtained greater than $8M of funding from American Heart Association and The National Institutes of Health to support his important work. A small sample of his work: https://lnkd.in/e6UbB-qx https://lnkd.in/efAJVQB6? Congrats also to all 4 amazing finalists including Kashish Goel, Tim P Van de Hoef, and co-winner Robert Avram.

Takeaways from the TCT MedTech Innovation Forum: In the first session, Shining a Light on the Path Ahead, moderators Andrew Cleeland and Amr Salahieh, Shifamed asked panelists for insights on the major issues shaping the medtech industry today: ➡ Financing: With few exits filling VC coffers, the predominance of inside rounds continues. However, there have been a few “green shoots” and as exits pick up, we will see more investments. "It's a cycle," said Josh Makower, Stanford Mussallem Center for Biodesign. "If it's down, it's going to go up. If it's way up, it's probably going to go down." One tip for founders from Amr Salahieh: Choose projects that are critically important to strategics. This gives you some ability to exit earlier even though most companies are being sold at a much later stage than before. “We try to be at the center of value for the very large strategics,” he said. ➡ Reimbursement: “Reimbursement in its current state is breaking the venture model,” said Josh Makower. Venture funds have a ten-year life – it doesn't work if 5.7 years of it is waiting for nominal reimbursement plus the time it takes to get anything truly big and novel through regulatory, commercialize, and achieve patient access. Calling on the entire ecosystem, Makower suggested elevating the issue - directly with CMS, through congressional representatives, and through powerful groups like the AMA. “We have to change things so that our industry can continue working to save and improve lives,” he said. ➡ Acquisition trends: Sean Salmon, Medtronic pointed out that venture teams have become more selective. “They are increasingly interested in operational issues that could be stumbling blocks once a company is acquired,” he said. Noting that ~67% of Class 1 recalls were for acquired products, Salmon said strategics want operational excellence in design history, quality management, and supply chain. Jan Garfinkle, Arboretum Ventures offered another strategy to help companies become attractive acquisition targets: mitigating risk through clinical trial design. One approach - conducting a pilot study as an RCT in order to observe treatment group results and control group results before filing to run a pivotal trial. Though expensive, it can lessen the risk of surprise control results. Pointing out that using medical technology devices involves a procedure that will evolve over time, Todd Brinton, MD, Edwards Lifesciences suggested that companies looking to be acquired set themselves up for the long haul by committing early to continued evidence development, a necessary exchange in evolving CMS programs for earlier reimbursement. “You have to think like a strategic," he said. "Getting on the market without payment isn't enough." #learnfromthebest #TCT2024 Cardiovascular Research Foundation